Cart
×
Get in the Game
Accessible gaming for people with Duchenne Individuals with Duchenne are living at a time when technology is helping to make the digital world more accessible and the real world more […]
Nationwide’s Success Has a Broad Impact on Duchenne Research
Kevin Flanigan, MD is a leading expert in the development of gene therapies for Duchenne, and the director of the Center for Gene Therapy in the Abigail Wexner Research Institute […]
Finding A Way on Father’s Day
Happy Father’s Day to all of the dads out there who have either found a way – or made one – so that their kids can experience their best life.
– Paul Miller, aka Hawken’s dad
Books About Duchenne For Children and Parents
Enjoy this hand-picked selection of books about Duchenne muscular dystrophy for children and parents. If you would like to add a book to this list, please let us know! Email: […]
Complex Medical Equipment Justification, Appeals and Resources
Insurance companies continue to deny complex medical equipment for patients whom it is medically necessary. The rules keep changing. It can be difficult to keep up with the latest equipment […]
Code Bio and Takeda to Develop Gene Therapies for Rare Diseases
We’re thrilled to share news about Code Biotherapeutics, a company pioneering targeted non-viral delivery of genetic medicines. CureDuchenne’s April 2021 research investment into Code Biotherapeutics was based on extensive preclinical […]
CureDuchenne Link at NORD Breakthrough Summit 2021
The 2021 National Organization for Rare Disorders (NORD) Breakthrough Summit saw a number of innovations unveiled for the rare disease community. RareDisease Advisor was there to cover the highlights of […]
CureDuchenne Joins AMP BGTC
CureDuchenne joins forces with NIH, FDA, and private organizations to increase effective gene therapies for rare diseases CureDuchenne is delighted to be a partner in the Accelerating Medicines Partnership Bespoke […]
WMS 2021 Day 5: Late-breaking News
In WMS 2021’s final day and “late-breaking news” session, Capricor Therapeutics announced positive final data from its Phase 2 HOPE-2 clinical trial in Duchenne patients treated with CAP-1002. HOPE-2 was […]